Privatsphäre-Einstellungen

Das forschende Pharmaunternehmen der Zukunft als wertorientiertes Netzwerk

Dr. Harald Pacl^a, Dr. Roland Mohr^b und Marcus Hartmann^c

Aventis Pharma Deutschland GmbH, Frankfurt/Main^a, Infraserv Höchst GmbH, Frankfurt/Main^b, und Forschungsgruppe Wirtschaftschemie am Institut für Chemie der Technischen Universität Berlin^c

The global pharmaceutical industry is currently struggling for growth. The lack of promising development pipelines is evident and the important patentprotected commercialization period continues to get shorter. Synergies from merger and acquisition activities may alleviate these effects in the short run. However, in the medium-term new business models are crucial for above-average success in the marketplace. This article aims to meet this challenge by describing the future pharmaceutical company as a value-based network. It concentrates on R&D as the core corporate function responsible for driving growth. The described network allows for an increased flexibility as a response to the dynamically changing environment. In order to form the cornerstone of the pharmaceutical company of the future the only structural prerequisite is the design of the minimum required decision-making bodies including the definition of key processes, which are necessary to foster innovation when operating in networks.